Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2011-5-2
pubmed:abstractText
Hypertension is a typical modern lifestyle-related disease that is closely associated with the development of cardiovascular disorders. Elevation of angiotensin II (ANG II) is one of several critical factors for hypertension and heart failure; however, the mechanisms underlying the ANG II-mediated pathogenesis are still poorly understood. Here, we show that ANG II-mediated cardiac fibrosis, but not hypertrophy, is regulated by interferon regulatory factor 3 (IRF3), which until now has been exclusively studied in the innate immune system. In a ANG II-infusion mouse model (3.0 mg/kg/d), we compared IRF3-deficient mice (Irf3(-/-)/Bcl2l12(-/-)) with matched wild-type (WT) controls. The development of cardiac fibrosis [3.95 ± 0.62% (WT) vs. 1.41 ± 0.46% (Irf3(-/-)/Bcl2l12(-/-)); P<0.01] and accompanied reduction in left ventricle end-diastolic dimension [2.89 ± 0.10 mm (WT) vs. 3.51 ± 0.15 mm (Irf3(-/-)/Bcl2l12(-/-)); P=0.012] are strongly suppressed in Irf3(-/-)/Bcl2l12(-/-) mice, whereas hypertrophy still develops. Further, we provide evidence for the activation of IRF3 by ANG II signaling in mouse cardiac fibroblasts. Unlike the activation of IRF3 by innate immune receptors, IRF3 activation by ANG II is unique in that it is activated through the canonical ERK signaling pathway. Thus, our present study reveals a hitherto unrecognized function of IRF3 in cardiac remodeling, providing new insight into the progression of hypertension-induced cardiac pathogenesis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1530-6860
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1531-43
pubmed:dateRevised
2011-11-11
pubmed:meshHeading
pubmed-meshheading:21266535-Angiotensin II, pubmed-meshheading:21266535-Animals, pubmed-meshheading:21266535-Antigens, CD45, pubmed-meshheading:21266535-Apoptosis, pubmed-meshheading:21266535-Blotting, Western, pubmed-meshheading:21266535-Bone Marrow Transplantation, pubmed-meshheading:21266535-Cardiomegaly, pubmed-meshheading:21266535-Cell Proliferation, pubmed-meshheading:21266535-Cells, Cultured, pubmed-meshheading:21266535-DNA, Complementary, pubmed-meshheading:21266535-Echocardiography, pubmed-meshheading:21266535-Fibrosis, pubmed-meshheading:21266535-Gene Expression Profiling, pubmed-meshheading:21266535-Hypertension, pubmed-meshheading:21266535-Immunity, Innate, pubmed-meshheading:21266535-Interferon Regulatory Factor-3, pubmed-meshheading:21266535-Mice, pubmed-meshheading:21266535-Mice, Inbred ICR, pubmed-meshheading:21266535-Mice, Knockout, pubmed-meshheading:21266535-Proto-Oncogene Proteins c-bcl-2, pubmed-meshheading:21266535-Ventricular Remodeling
pubmed:year
2011
pubmed:articleTitle
IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension.
pubmed:affiliation
Department of Immunology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't